Doctronic navigation menu Log In
Doctronic navigation menu

Contents
  • Deciding When to Switch
  • Understanding High-Efficacy DMTs
  • The Role of Shared Decision-Making

Navigating MS Treatments: What Are Your Options?

Navigating MS Treatments: What Are Your Options?

Exploring Choices

The world of MS treatments can be overwhelming. Let's break down the options to help you find what might work best.
Contents
  • Deciding When to Switch
  • Understanding High-Efficacy DMTs
  • The Role of Shared Decision-Making

Deciding When to Switch

When MS symptoms persist despite treatment, switching therapies might be necessary. Factors like disease activity on MRI and frequency of relapses guide this decision. Collaboration between patients and healthcare providers ensures the best treatment adjustments.

Understanding High-Efficacy DMTs

Some MS drugs, like natalizumab and ocrelizumab, offer high efficacy in controlling disease activity. These options are often considered for patients who don't respond to less effective treatments. However, they come with their own set of risks and require careful monitoring.
Multiple Sclerosis (MS) is a chronic illness involving your central nervous system (CNS). The immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.

The Role of Shared Decision-Making

Choosing the right therapy involves shared decision-making between you and your healthcare team. This process considers your preferences, lifestyle, and the potential benefits and risks of each treatment. Open communication is key to finding the best fit.

FAQs

When should MS treatment be switched?

When symptoms persist despite current treatment.

What are high-efficacy DMTs?

Drugs like natalizumab and ocrelizumab that offer strong disease control.

What is shared decision-making?

A process involving both patient and healthcare team in treatment choices.

The Bottom Line

Navigating MS treatments is a personal journey requiring informed choices.
Start exploring: Consult Doctronic to discuss your MS treatment options today.
Additional References
  1. Lu G, Beadnall HN, Barton J, et al. The evolution of 'No Evidence of Disease Activity' in multiple sclerosis. Mult Scler Relat Disord 2018; 20:231.
  2. Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurol Ther 2019; 8:241.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.